News

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Novo Nordisk (NVO) downgraded to Hold by HSBC amid growth concerns, GLP-1 market challenges, and revised 2025-2026 earnings ...
Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...
Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.
Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO. Doustdar will succeed Lars Fruergaard Jørgensen, whose surprise abdication was ...